Stayble Therapeutics presents at Stora Aktiedagen in Gothenburg

November 2022

Andreas Gerward, CEO of Stayble Therapeutics AB, will attend Stora Aktiedagen in Gothenburg on 8 November 2022. Topics to be discussed include Stayble’s market potential, the ongoing Phase IIb study and the way forward with ongoing partner discussions and the regulatory preparations for the Phase III study.

On Tuesday 8, Stayble Therapeutics will participate in Aktiespararnas event from 11.00-11.30. Andreas Gerward will present the company and answer questions. Watch the presentation live on the web, via The event is open to everyone and does not require membership of Aktiespararna. No registration is required to follow the event digitally.


Take the opportunity to ask Andreas your questions by texting 079-347 98 45 or emailing The moderator will ask questions during the Q&A session after the presentation. You can submit your questions now or at the presentation.



When: 8 November, 11.00-11.30

Live webcast:


The recorded presentation will be published on the Stayble website after the presentation.  


For more information

Andreas Gerward, CEO Stayble Therapeutics AB


Phone: +46 730 808 397


About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.


Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail